



Cardiovascular Disease-Related Parameters and Oxidative Stress in SHROB Rats, a Model for Metabolic Syndrome

Eunice Molinar-Toribio¹, Jara Pérez-Jiménez^{1*}✉, Sara Ramos-Romero^{1,2}, Laura Lluís³, Vanessa Sánchez-Martos³, Núria Taltavull³, Marta Romeu³, Manuel Pazos⁴, Lucía Méndez⁴, Aníbal Miranda^{5,6}, Marta Cascante^{5,6}, Isabel Medina⁴, Josep Lluís Torres¹

1 Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain, **2** Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Zaragoza, Spain, **3** Unidad de Farmacología, Facultad de Medicina y Ciencias de la Salud, Universidad Rovira i Virgili, Reus, Spain, **4** Instituto de Investigaciones Marinas (IIM-CSIC), Vigo, Spain, **5** Department of Biochemistry and Molecular Biology, IBUB and unit associated with CSIC, Faculty of Biology, Universitat de Barcelona, Barcelona, Spain, **6** Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Abstract

SHROB rats have been suggested as a model for metabolic syndrome (MetS) as a situation prior to the onset of CVD or type-2 diabetes, but information on descriptive biochemical parameters for this model is limited. Here, we extensively evaluate parameters related to CVD and oxidative stress (OS) in SHROB rats. SHROB rats were monitored for 15 weeks and compared to a control group of Wistar rats. Body weight was recorded weekly. At the end of the study, parameters related to CVD and OS were evaluated in plasma, urine and different organs. SHROB rats presented statistically significant differences from Wistar rats in CVD risk factors: total cholesterol, LDL-cholesterol, triglycerides, apoA1, apoB100, abdominal fat, insulin, blood pressure, C-reactive protein, ICAM-1 and PAI-1. In adipose tissue, liver and brain, the endogenous antioxidant systems were activated, yet there was no significant oxidative damage to lipids (MDA) or proteins (carbonylation). We conclude that SHROB rats present significant alterations in parameters related to inflammation, endothelial dysfunction, thrombotic activity, insulin resistance and OS measured in plasma as well as enhanced redox defence systems in vital organs that will be useful as markers of MetS and CVD for nutrition interventions.

Citation: Molinar-Toribio E, Pérez-Jiménez J, Ramos-Romero S, Lluís L, Sánchez-Martos V, et al. (2014) Cardiovascular Disease-Related Parameters and Oxidative Stress in SHROB Rats, a Model for Metabolic Syndrome. PLoS ONE 9(8): e104637. doi:10.1371/journal.pone.0104637

Editor: Christopher Torrens, University of Southampton, United Kingdom

Received: February 17, 2014; **Accepted:** July 10, 2014; **Published:** August 12, 2014

Copyright: © 2014 Molinar-Toribio et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by the Spanish Ministries of Science and Innovation and of Economy and Competitiveness (Grants AGL2009-12374-C03-01, -02 and -03; AGL2013-49079-C2-1,2-R; respectively) and in part by the Generalitat de Catalunya regional authorities (2009SGR-1308). M.C. acknowledges ETHERPATHS (FP7-KBBE-222639) funded by the European Union and "ICREA Academia" award for excellence in research, funded by the ICREA Foundation of the Generalitat de Catalunya. The Panamanian Government (SENACYT/IFRHU) and the Spanish Ministry of Science and Innovation awarded graduate fellowships to E.M.-T. and L.M., respectively. The ISCIII and the Xunta de Galicia are also acknowledged for "Sara Borrell" and "Isidro Parga Pondal" postdoctoral contracts to J.P.-J. (CD09/00068) and M.P., respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: jara.perez@ictan.csic.es

✉ Current address: Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN-CSIC), Madrid, Spain

Introduction

The combination of CVD risk factors known as metabolic syndrome (MetS) is becoming a major public health problem which now affects 20%–30% of the adult population in developed countries [1]. The risk factors include abdominal obesity, hyperglycaemia, hypertension and/or hypertriglyceridaemia associated with a sedentary lifestyle [2]. The main underlying disorder in MetS appears to be insulin resistance, i.e., an impairment of insulin action within tissues (mainly muscle, liver and adipose tissues) that has been related to chronic low-level inflammation as well as oxidative stress (OS), as second-order underlying mechanisms for this pathological condition [3,4]. The factors defining MetS may lead to the onset of type-2 diabetes and CVD. This is the main reason why the study of the factors underlying MetS can be clinically useful.

There is wide interest in the development of strategies for the prevention of MetS, mainly via two different approaches: a)

pharmacology – based on the use of drugs such as certain statins or AMPK (5' adenosine monophosphate-activated protein kinase) activating agents [5,6]; and b) nutrition-based on diet supplementation with functional compounds, e.g., proanthocyanidins [7] or iminosugars [8].

To test the efficacy of the different approaches, several animal models of MetS have been suggested, in which MetS is either induced by the diet [9,10] or results from some genetic alteration. Most of the genetically modified animals present mutations in the gene that codes for the leptin receptor [11], which impairs the capacity of leptin to regulate food intake and eventually leads to the development of insulin resistance. One such model is SHROB (spontaneously hypertensive obese) rats, also called Koletsky rats [12,13]. SHROB rats were generated by crossing a female spontaneously hypertensive rat (SHR), obtained by breeding high-blood-pressure Wistar-Kyoto rats, with a normotensive Sprague Dawley male, from which a single homozygous recessive trait

appeared. That trait is a nonsense mutation in the leptin receptor, designated fa^k , which results in a premature stop codon in the extracellular domain of the leptin receptor that circumvents the process of transduction and thereby truncates all the leptin receptors [14,15]. SHROB rats, homozygous for this mutation, are therefore characterized by monogenetic obesity combined with a hypertensive background for which several phenotype aspects have been described, including hyperinsulinaemia, hyperlipidaemia and nephropathy [15]. SHROB rats are thus a model for MetS, in accordance with some of its currently accepted defining factors, i.e., insulin resistance, hypertension, increased plasma triglyceride levels and obesity [16]. It has also been suggested that in SHROB rats hyperinsulinaemia is not accompanied by hyperglycaemia, this model would be especially useful for the study of the prediabetic state [17], in contrast to other animal models (e.g. Zucker rats) which develop type-2 diabetes.

Despite its use as a model of MetS, a complete description of the SHROB rat phenotype, in relation to markers related to CVD and particularly OS, is lacking. Moreover, studies with SHROB rats have compared them with SHR, spontaneously hypertensive rats [15,18], a rat that is already mutated and in which several parameters are altered, and not with either of the original rat strains from which these rats were derived, i.e., Sprague-Dawley or Wistar Kyoto (WKY) rats.

The aim of this work is to complete a phenotypic description of SHROB rats using previously unexplored parameters related to CVD, and compare it with that of non-mutated WKY rats. We obtained new data of relevance for the use of SHROB rats in nutrition studies.

Materials and Methods

Materials and reagents

The A04 diet was from Harlan Iberica (Panlab S.L., Barcelona, Spain). Soybean oil, obtained from unrefined organic soy oil (first cold pressing), was from Clearspring Ltd. (London, UK).

Ketamine chlorhydrate was from Merial Laboratorios (Barcelona, Spain). Xylazine was from Quimica Farmaceutica (Barcelona, Spain). [2H4]-15-F2t-IsoP, 15-F_{2t}-IsoP and 15-F_{2t}-IsoP methyl ester were obtained from Cayman Chemical (Ann Arbor, MI, USA). 2,3,4,5,6-Pentafluorobenzyl (PFB) bromide, N,N-diisopropylethylamine (DIPE), acetonitrile, anhydrous sodium sulphate, heptane, phenylmethylsulphonyl fluoride (PMSF), dithiothreitol (DTT), iodoacetamide, ethylenediaminetetraacetic acid (EDTA), Tris-HCl, 3,3-cholaminopropyl-dimethylammonio-1-propanesulphonate (CHAPS), anhydrous magnesium chloride, bicinchoninic acid (BCA), 2,2'-Azobis(2-amidinopropane) dihydrochloride (AAPH), 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), fluorescein (sodium salt), acetone, phosphomolybdic acid, Bradford reagent, NADPH (β -Nicotinamide adenine dinucleotide 2'-phosphate reduced tetrasodium salt hydrate), glutathione reductase (GR from baker's yeast), L-glutathione reduced (GSH minimum 99%), t-tert-butyl hydroperoxide (t-BuOOH) and L-glutathione oxidized (GSSG) were all obtained from Sigma-Aldrich (St. Louis, MO, USA). N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) was from Supelco (Bellefonte, PA, USA). Hydrochloric acid fuming 37%, ethanol absolute, ethyl acetate, methanol, chloroform, Na₂CO₃, NaHCO₃, EDTA Na²⁺, o-phthalaldehyde (OPT), N-ethylmaleimide (NEM) and thiobarbituric acid were purchased from Merck KGaA (Darmstadt, Germany). Fluorescein-5-thiosemicarbazide (FTSC) was purchased from Invitrogen (Carlsbad, CA, USA). ProteoBlock protease inhibitor cocktail was purchased from Thermo Fisher Scientific Inc. (Rockford, IL, USA). Urea,

thiourea, SDS, glycine and glycerol were obtained from USB (Cleveland, OH, USA). Ammonium persulphate (APS), IPG buffer, pharmalyte 3-10; bromophenol blue and 1,2-bis(dimethylamino)-ethane (TEMED) were purchased from GE Healthcare Bio-Sciences AB (Uppsala, Sweden). Acrylamide, bis (N,N'-methylene-bis-acrylamide) and the Bio-Rad protein assay were obtained from Bio-rad (Hercules, CA, USA). Drabkin Reagent and albumin were purchased from Quimica Clinica Aplicada (Tarragona, Spain). Na₂HPO₄, NaH₂PO₄, NaCl, epinefrine, KH₂PO₄, K₂HPO₄, trichloroacetic acid (TCA) and NaOH were purchased from Panreac Quimica (Barcelona, Spain). Water for the assay solutions was obtained using a Milli-Q water purification system from Millipore Corporation (Billerica, MA, USA).

Animals

Seven female, 11- to 14-week-old, spontaneously hypertensive obese rats (SHROB) (Charles River Laboratories, Wilmington, MA, USA) and seven female, 11-week-old WKY rats (control group) (Janvier, Le Genest-St-Isle, France) were used. They were kept away from male rats to minimize hormonal alterations.

Experimental design

The rats were kept in Macrolon cages ($n = 2-3/\text{cage}$, 425×265×180 mm) under controlled conditions of stable humidity ($50 \pm 10\%$), and temperature ($22 \pm 2^\circ\text{C}$) with a 12:12-h light/dark cycle. All the groups were fed a standard pelleted A04 diet, given water (Ribes, Barcelona, Spain) *ad libitum* and administered a weekly oral dose of 0.8 mL/kg of soybean oil for 13-weeks-fatty acid composition provided as **Table S1**. The additional dose of fat (weekly excess of 5–10% of fat intake) was intended to accelerate the appearance of alterations in CV risk factors and OS related parameters. At week 15, one week after the last intragastric dose of soybean oil and oral glucose tolerance test (OGTT)—see below—the rats were fasted overnight, anesthetized intraperitoneally with ketamine and xylazine (80 mg/kg and 10 mg/kg body weight respectively), and then killed by exsanguination. All the procedures follow the European Union guidelines for the care and management of laboratory animals and all efforts were made to minimize suffering. The pertinent permission for this specific study was obtained from the CSIC (Spanish Research Council) Subcommittee of Bioethical Issues (ref. AGL2009-12 374-C03-03).

Sample collection

For urine collection, at week 12 of the experiment, the rats were placed in metabolic cages and deprived of food for 18 h; the animals had previously been acclimated to the metabolic cages. At the end of the experimental period, after one week of recuperation since the final intragastric dose of soybean oil, blood was collected by cardiac puncture under anaesthesia. Plasma, serum and erythrocytes were collected. Tissue samples collected from heart, brain, liver, and kidney were washed with 0.9% NaCl solution and immediately frozen in liquid nitrogen. Abdominal fat was weighed and immediately frozen. All the samples were stored at -80°C pending analysis. Before analysis, tissue samples were homogenized with sodium phosphate buffer and ultra-centrifuged.

Cardiovascular disease risk factors

Body weight was monitored weekly throughout the experiment.

Determination of plasma lipid profile. Total plasma cholesterol (CHOL), LDL-cholesterol (LDLc), HDL-cholesterol (HDLc) and triglycerides (TG) were measured by spectrophotometric methods using the corresponding kits from Spinreact

(Girona, Spain). ApoA1 and ApoB100 were measured using ELISA kits purchased from Cusabio Biotech (Hubei, China)

Determination of glycaemia. Blood glucose levels were measured by the enzyme electrode method using an Ascensia ELITE XL blood glucose meter from (Bayer Consumer Care (Basel, Switzerland). Plasma insulin was measured using ELISA kits from Millipore (Billerica, MA, USA). Homeostasis model assessments (HOMA) were calculated by applying the formula: fasting plasma glucose (mg/dL) times fasting insulin (mU/L) divided by 405 [19]. Glycated Hb was measured using a spectrophotometric kit from Spinreact. All these measurements were carried out at the end of the study.

An OGTT was conducted at week 14 of the experiment after 18 h of food deprivation. Rats were administered a glucose dose of 2 g/kg body weight by gastric probe using a 29% glucose solution. The glucose concentration was measured by the enzyme electrode method, using single drops of blood taken from the saphenous vein at 0, 15, 30, 45, 60, 90 and 120 min after glucose administration. The AUC for serum glucose was calculated over the 2 h period. This test was carried out 1 week after the last intragastric dose of soybean oil.

Blood pressure. Systolic and diastolic blood pressure were measured at week 13 of the experiment. In a quiet place, at an established time to reduce circadian rhythm interference, the rats were restrained in a rat pocket and maintained at 32°C. Systolic and diastolic blood pressure were measured three times by the tail-cuff method, using a non-invasive automatic blood pressure analyser (Panlab, Barcelona, Spain) as previously described [20]. Data are presented as the mean of three measurements.

Markers of endothelial function, inflammation and thrombotic activity. The corresponding ELISA kits from Cusabio Biotech (Hubei, China) were used to measure the following parameters in plasma: vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) as markers of endothelial function; C-reactive protein (CRP) as an inflammation marker.; plasminogen activator inhibitor-1 (PAI-1) as a marker of thrombotic activity.

Endogenous antioxidant systems

Activity of superoxide dismutase (SOD) and catalase (CAT). SOD and CAT activities were measured using standard spectrophotometric methods [21,22] in the following samples: erythrocytes (0.23–1.84 μ L and 0.5 μ L, respectively), liver (167–417 μ g and 1.25 mg, respectively), abdominal fat (1.6–4 μ g and 12 mg, respectively), kidney (667–1667 μ g and 10 mg, respectively), heart (333–833 μ g and 5 mg, respectively) and brain (833–417 μ g and 5 mg, respectively).

Glutathione system. Glutathione peroxidase (GPx) and glutathione reductase (GR) activities were measured by spectrophotometric methods [23,24]. Glutathione (GSH) and glutathione disulphide (GSSG) were determined using fluorometric methods [25].

GR and GPx analysis were measured in the following samples: erythrocytes (8–48 μ L), liver (40–240 μ g), abdominal fat (2–12 mg), kidney (80–480 μ g), heart (80–480 μ g) and brain (500–3000 μ g). GSH and GSSG were measured in erythrocytes (149 μ L), liver (75 μ g), abdominal fat (372 μ g), kidney (298 μ g), heart (149 μ g) and brain (372 μ g). The standard curves used for the quantification of GSH and GSSG are provided as **Figures S1 and S2**.

In both cases, the activities of the enzymes were normalized to the amount of protein by the Bradford method [26] and to the amount of Hb in erythrocytes by the Drabkin method [27].

Oxidative stress

Determination of oxygen radical absorbance capacity. Total plasma antioxidant capacity was measured as the oxygen radical absorbance capacity (ORAC) [28], which measures the level of protection from the loss of intensity of the fluorescent molecules fluorescein, due to the action of peroxy radicals generated from an azo-initiator. A standard curve for Trolox (reference compound for antioxidant capacity determination) was prepared in the range 12.5–100 μ M.

Protein carbonylation. Protein concentrations in the homogenates were determined according to the method of Bradford [26], using a standard curve between 0.125 and 0.975 mg protein/mL standard. Preparation of homogenates from liver aliquots, determination of the protein concentration in the homogenates and protein separation by 10% SDS-PAGE proteins from 250 mg liver were fractionated according to hydrophobicity, into proteins soluble at low ionic strength, mostly water-soluble proteins, and proteins soluble at high ionic strength, mostly hydrophobic proteins. After homogenization, each liver fraction (300 μ L) and plasma (25 μ L) were independently incubated with 1 mM fluorescein-5-thiosemicarbazide (FTSC) in the dark as previously described [29,30]. After incubation, the proteins were precipitated with an equal volume of 20% TCA (v/v), centrifuged and finally, re-dissolved in urea buffer (7 M urea, 2 M thiourea, 2% CHAPS, 0.5% Pharmalyte 3–10, 0.5% IPG 3–10 buffer and 0.4% DTT). To evaluate the protein carbonyl levels, 30 μ g of each sample were subjected to one-dimensional (1-DE) 10% SDS-PAGE [31] and run in a Mini-protean 3 cell (Bio-Rad). After electrophoresis, FTSC-tagged proteins were visualized by exposing the gel to a UV transilluminator Molecular Imager Gel Doc XR System (Bio-Rad) equipped with a 520 nm band-pass filter (520DF30 62 mm) and the scanned one-dimensional gels were analysed with the 1-D gel analysis software LabImage 1D from Kapelan Bio-Imaging Solutions (Halle, Germany). Finally, the scanned analysed gels were stained overnight with the Coomassie dye PhastGel Blue R-350 (GE Healthcare, Little Chalfont, UK) to visualize the total amount of protein in each sample. The global protein carbonylation level for each sample was quantified based on the overall optical volume of each lane in the FTSC-stained 1-D electrophoresis gel, whereas the oxidation level of a specific protein band was estimated by its optical intensity (peak height). Oxidized albumin (1 to 14 μ g) was used as a positive control.

Oxidized LDL. Plasma oxidized LDL (LDL-ox) was determined with an ELISA kit from Cusabio Biotech, by measuring the absorbance at 450 nm on a PowerWave XS2 spectrophotometer from BioTec Instruments, Inc., (Winooski, VT, USA).

Malondialdehyde (MDA). MDA concentrations were measured in homogenized liver (80 μ g of sample), kidney (80 μ g), abdominal fat (80 μ g), heart (10 μ g) and brain (400 μ g) with fluorescence detection [32]. The fluorescence at 515 nm excitation wavelength and 548 nm emission wavelength was determined on an LS50B spectrofluorimeter (Perkin Elmer, Alabama, USA).

Determination of isoprostane 15-F_{2t}-IsoP. Urine 15-F_{2t}-IsoP was determined by GC/negative ion chemical ionization/MS (GC-NICI-MS) following the method of Milne *et al.* [33]. Briefly, after addition of the deuterated internal standard [2H₄]-15-F_{2t}-IsoP to 250 μ L of urine, the samples were subjected to solid phase extraction (SPE) purification, with a C18 Sep-Pak column and a silica Sep-Pak column (both from Waters Associates, Milford, MA, USA). The F₂-Isoprostanes were derivatized to pentafluorobenzyl (PFB) esters and further purified by thin layer chromatography (TLC) using 15-F_{2t}-IsoP methyl ester as the reference compound with an R_F value identical to the analyte. Finally, the pure derivatized analytes were converted to trimethylsilyl ether

derivatives and analysed by GC-NICI-MS using a Shimadzu QP201 instrument (Tokyo, Japan), fitted with a DB1701 fused silica capillary column (15 m×0.25 mm i.d., 0.25 μM film thickness) from Agilent (J & W Scientific, Folsom, CA, USA). The 15-F_{2t}-IsoP ion monitored was the carboxylate anion at *m/z* 569. Representative chromatograms used for the determination of 15-F_{2t}-IsoP are provided as **Figure S3**. The final results are expressed in ng/mg creatinine. Creatinine levels from the urine samples were determined by a colorimetric method using a commercial kit from C-cromatest Linear Chemicals (Barcelona, Spain) by measuring absorbance at 510 nm on a SpectraMax M5 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).

Statistical analysis

The different analytical determinations in the biological samples were carried out in duplicate or triplicate, depending on the method. Results are expressed as the mean + SEM. The non-parametric Mann-Whitney U's test was applied to analyse the significant differences ($P<0.05$) between groups. The SPSS IBM19 package for Windows was used throughout.

The weight distribution between the groups of rats at each of the 15 time points was compared using the Wilcoxon Rank Sum test. Due to the large number of comparisons, a multi-test procedure that applies multiple comparisons as is known as the false discovery rate (FDR) [34] correction, with Simes' method [35] was used. With this procedure a comparison was considered statistically significant if the corresponding *p*-value was lower than or equal to the specific α -corrected value for the comparison. This analysis was performed using the statistical software STATA 12.0.

Results

Cardiovascular disease risk factors

The SHROB rats were already obese at week 16, with a body weight twice that of the WKY rats (483±9 g versus 221±4 g). Moreover, while the WKY rats maintained a constant body weight up to week 27, the SHROB rats showed an increase from 476.8±15.9 g at week 16 to 605.6±19.5 g at week 27. **Figure S4** shows the evolution of body weight of the SHROB and WKY rats during the study.

Abdominal fat at the end of the study, expressed as percentage of body weight was 50% higher in the SHROB than in the WKY rats (**Table 1**).

Plasma lipid profile. The SHROB rats presented significantly higher ($P<0.01$) levels of plasma total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides than the WKY rats (**Table 1**). In particular, the SHROB rats showed a ninefold increase in total cholesterol and more than a tenfold increase in triglycerides, compared to the WKY rats. Plasma levels of both the anti-atherogenic ApoA1 and the pro-atherogenic Apo B100 were also significantly higher ($P<0.01$) in the SHROB rats than in the WKY rats (+33% and +62%, respectively).

Glycaemia. No significant differences were observed in fasting plasma glucose, OGTT or in glycated Hb between the SHROB and WKY rats. In contrast, plasma insulin was significantly higher ($P<0.01$) in the SHROB rats than in the WKY rats (1.0±0.3 nM versus 0.3±0.1 nM, respectively), and consequently, the HOMA index was also higher in the SHROB rats (**Table 1**).

Blood pressure. Both systolic and diastolic blood pressure were significantly higher ($P<0.001$) in the SHROB rats (193±12 mmHg and 135±5 mmHg, respectively) than in the WKY rats (121±2 mmHg and 106±2 mmHg) (**Table 1**).

Endothelial dysfunction. ICAM-1 and VCAM-1 were measured as markers of endothelial dysfunction; considered the earliest stage in the atherosclerosis process. ICAM-1 showed an 84% increase in plasma levels in the SHROB rats compared to the WKY rats ($P<0.001$). No significant differences were found in plasma VCAM-1 between the SHROB and WKY rats (**Table 1**).

Inflammation. Plasma C-reactive protein, determined as a marker of inflammation, was 65% higher in the SHROB rats than in the WKY rats ($P<0.001$) (**Table 1**).

Thrombotic activity. The SHROB rats presented significantly higher ($P<0.001$) plasma levels of PAI-1 than the WKY rats (6.4±0.3 μg/mL versus 11.6±0.5 μg/mL, respectively) (**Table 1**).

Endogenous antioxidant systems

Endogenous antioxidant systems were evaluated in erythrocytes, tissues and organs of the SHROB and WKY rats at the end of the study (**Table 2**).

SOD and CAT activity. The activity of the endogenous antioxidant enzymes was measured in erythrocytes, liver, abdominal fat, kidney and heart. No significant differences in SOD activity between SHROB and WKY rats were observed in any of the samples analysed. As regards CAT activity, brain was the only organ where significant differences ($P<0.01$) were found between the SHROB and WKY rats.

Glutathione system. The status of the glutathione system was evaluated by quantifying the two forms of glutathione (GSH and GSSG) to calculate the GSH/GSSG ratio; and by measuring the activity of the associated enzymes (GR, which regenerates reduced glutathione; and GPx, which catalyses the oxidation of GSH to GSSG). Higher concentrations of GSH in liver ($P<0.01$), abdominal fat ($P<0.05$) and brain ($P<0.01$) were found in the SHROB rats than the WKY rats. GSH/GSSG was significantly ($P<0.05$) higher in the adipose tissue of the SHROB rats. GPx activity was also higher in the abdominal fat tissue ($P<0.001$) and brain ($P<0.01$) of the SHROB rats. In contrast, higher concentration of GSSG were found in the heart of the SHROB rats than in the WKY rats ($P<0.01$) and the SHROB rats showed lower GPx activity in erythrocytes and in liver ($P<0.05$) and lower GR activity in liver ($P<0.05$).

Oxidative stress

Several biomarkers of OS were measured in blood, urine and different organs in the SHROB and WKY rats (**Table 3**). Plasma antioxidant capacity, as determined by ORAC assay, was significantly ($P<0.05$) higher in the SHROB than in the WKY rats. Lipid oxidation was evaluated by determining oxidized LDL in plasma, MDA in liver, kidney, abdominal fat, heart and brain, and 15-F_{2t}-IsoP in urine. Oxidized LDL in plasma was 50% higher in the SHROB rats than in the WKY rats, although this increase did not reach significance, due to the high interindividual variability of this parameter. Similarly, isoprostane 15-F_{2t}-IsoP in urine was non-significantly higher in the urine of SHROB rats. Creatinine was higher in SHROB rats than in WKY rats (68 mg/dL SEM 9 vs 58 mg/dL SEM 7); since 15-F_{2t}-IsoP is expressed per mg of creatinine, the higher values of this isoprostane in the SHROB rats is not an artefact resulting from increased creatinine values. In contrast, MDA in abdominal fat was significantly lower ($P<0.05$) in SHROB rats than in WKY rats and overall protein oxidation-measured as total carbonyls-was lower in the SHROB than in the WKY rats in both the low and high ionic strength fractions of liver proteins ($P<0.05$) as well as in plasma ($P = 0.0571$).

Table 1. CVD risk factors evaluated in the plasma of SHROB and WKY rats (mean value and SEM)¹.

Category	Parameter	SHROB		WKY	
		Mean	SEM	Mean	SEM
Physical measurements	Abdominal fat (% bw)	6.7**	0.4	4.3	0.2
Plasma lipid profile	Total cholesterol (mM)	8.3**	1.2	3.3	0.2
	LDL-cholesterol (mM)	0.4*	0.1	0.1	0.004
	HDL-cholesterol (mM)	2.9*	0.2	1.9	0.1
	Total triglycerides (mM)	40.0**	0.0	5.6	1.1
	Apo A1 (mg/dL)	68.3*	1.9	51.4	5.0
	Apo B100 (mg/dL)	205.4*	18.7	126.8	5.3
Glycaemia	Glucose (mM)	3.4	0.1	3.5	0.1
	Insulin (nM)	1.0**	0.2.9	0.3	0.1
	HOMA index	15.6**	2.4	5.6	1.1
	OGTT (AUC)	5016.3	177.4	4494.0	122.8
	Glycated Hb (%)	6.8	0.4	6.4	0.4
Blood pressure	Systolic blood pressure (mmHg)	193.2**	12.5	121.0	2.2
	Diastolic blood pressure (mmHg)	134.8**	5.2	106.5	1.7
Endothelial dysfunction	VCAM-1 (µg/mL)	2.7	0.3	3.4	0.6
	ICAM-1 (ng/mL)	1.0**	0.1	0.5	0.03
Inflammation	C reactive protein (pg/mL)	285.9**	22.0	172.8	14.4
Thrombotic activity	PAI-1 (µg/mL)	11.6**	0.5	6.4	0.3

¹SHROB, Spontaneously Hypertensive Obese; WKY, Wistar Kyoto; OGTT, oral glucose tolerance test; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1; PAI-1, plasminogen activator inhibitor-1.

Statistically significant differences between the samples are indicated by * ($P<0.05$), ** ($P<0.01$) and *** ($P<0.001$).

doi:10.1371/journal.pone.0104637.t001

Discussion

SHROB rats represent a particularly interesting animal model for MetS, a situation prior to the onset of type-2 diabetes or CVD, in which the different metabolic alterations may be addressed without the use of drugs. The aim of the present study was to contribute to the description of this animal model, by examining parameters related to cardiovascular function, inflammation and oxidative stress not previously reported.

Total cholesterol, triglycerides, fasting glucose, insulin, glycated haemoglobin and blood pressure, have been examined before in SHROB rats [15,17] and in the related SHRSP (stroke-prone spontaneously hypertensive rat) model, after supplementation with soybean oil [36]. Our results concord with previous reports except for glycaemia; some authors found hyperglycaemia [15,37,38] while others reported normoglycaemia, [17,39], as we do. Anti-atherogenic ApoA1 and pro-atherogenic Apo B100 are now included in the lipid profile. Certain markers of endothelial dysfunction (ICAM-1 and VCAM-1), inflammation (C-reactive protein) and thrombotic activity (PAI-1) are also reported here for the first time.

The SHROB rats exhibited significant alterations in abdominal fat, plasma lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apoA1, apoB100), insulin, blood pressure, ICAM-1, C-reactive protein and PAI-1 (**Table 1**). In many of these parameters (lipid profile, markers of endothelial dysfunction, inflammation and thrombotic activity), the values in the SHROB rats were at least 50% higher than in the WKY rats. Impairment of endothelial function in SHROB rats has previously been related to alterations in the nitric oxide pathway and the presence of visceral prostaglandins derived from perivisceral adipose tissue [36,37]. All these results are consistent with high

circulating fat, visceral fat accumulation and the state of low-level inflammation that precedes insulin resistance [40]. Inflammation appears to be the link between obesity and the development of insulin resistance in MetS [41]. The mutation (fa^k) in the leptin receptor of SHROB rats that impairs the ability of leptin to regulate fat intake would explain these effects with a direct relation to an excess of fat.

Since OS is a complex process, where there are different interactions between endogenous antioxidants systems, progress of oxidation in biomolecules and levels of circulating exogenous antioxidants [42], we decided to measure markers corresponding to each one of these components of OS. The picture that emerges from our results is of a marked difference between systemic OS (as measured via the endogenous antioxidant system in erythrocytes and oxidized LDL in plasma) and OS in organs (as measured via the endogenous antioxidant system in tissues and organs, and via final lipid and protein oxidation products in organs and in urine). Both SOD and GPx activities in erythrocytes were significantly reduced in the SHROB rats, and this attenuation of the endogenous defence system was concomitant with a 50% increase in LDL oxidation. This is consistent with the preceding observations related to CVD biomarkers, since OS, particularly low SOD activity, has been shown to be present in subjects with MetS who also show high C-reactive protein levels [4]. However, this systemic OS was not immediately translated to the different organs, since the levels of MDA in liver and kidney and of 15-F_{2t}-IsoP in urine were not significantly modified in the SHROB rats. Indeed, compared to the WKY rats, the SHROB strain presented a significant increase in GSH in liver, abdominal fat and brain as well as a significant decrease in overall protein carbonylation and lipid oxidation in abdominal fat. We found that, in SHROB rats, OS may present later than other reported organ disturbances such

Table 2. Endogenous antioxidant systems in SHROB and WKY rats (mean value and SEM)¹.

Organ	Parameter	SHROB		WKY	
		Mean	SEM	Mean	SEM
Erythrocytes	SOD (U/g Hb)	768.0	224.0	1444.0	161.0
	CAT (mmol/min/g Hb)	51.9	4.1	41.5	13.1
	GR (U/g Hb)	0.9	0.1	0.9	0.1
	GPx (U/g Hb)	51.5*	10.3	101.5	14.4
Liver	SOD (U/g mg prot)	8.3	0.5	8.7	0.6
	CAT (μmol/min/mg prot)	70.8	9.8	81.1	10.9
	GR (mU/mg prot)	66.7*	3.1	88.8	8.3
	GPx (mU/mg prot)	245.4*	31.0	383.8	37.1
	GSH (nmol/mg prot)	61.2**	9.6	29.9	2.6
	GSSG (nmol/mg prot)	133.7	12.1	61.2	9.6
Abdominal fat	GSH/GSSG	0.5*	0.1	0.5	0.1
	SOD (U/g mg prot)	4.2	0.7	6.5	1.4
	CAT (μmol/min/mg prot)	27.8	4.9	28.3	2.5
	GR (mU/mg prot)	31.2	7.3	28.3	2.1
	GPx (mU/mg prot)	38.7**	2.6	15.8	4.0
	GSH (nmol/mg prot)	110.4*	24.9	41.7	6.4
	GSSG (nmol/mg prot)	49.8	4.8	47.7	3.0
Kidney	GSH/GSSG	2.2*	0.5	0.9	0.1
	SOD (U/g mg prot)	2.2	0.3	2.8	0.4
	CAT (μmol/min/mg prot)	24.1	3.1	33.5	7.6
	GR (mU/mg prot)	47.1	11.72	41.64	3.93
	GPx (mU/mg prot)	57.2	9.07	48.0	3.82
	GSH (nmol/mg prot)	33.4	7.4	36.7	3.7
	GSSG (nmol/mg prot)	0.5	0.1	0.6	0.1
Heart	GSH/GSSG	71.0	18.1	64.5	8.6
	SOD (U/g mg prot)	6.0	0.5	5.6	0.7
	CAT (μmol/min/mg prot)	15.1	0.6	13.4	1.1
	GR (mU/mg prot)	23.6	1.4	27.4	2.3
	GPx (mU/mg prot)	146.6	9.9	159.6	9.0
	GSH (nmol/mg prot)	21.5	2.8	18.1	2.1
	GSSG (nmol/mg prot)	6.4**	0.6	4.5	0.3
Brain	GSH/GSSG	3.4	0.5	4.0	0.5
	SOD (U/g mg prot)	8.0	0.2	7.4	1.5
	CAT (μmol/min/mg prot)	6.4**	0.9	2.2	0.7
	GR (mU/mg prot)	67.4	7.3	49.8	3.7
	GPx (mU/mg prot)	49.0**	5.3	30.9	1.5
	GSH (nmol/mg prot)	87.2**	16.5	24.2	7.3
	GSSG (nmol/mg prot)	5.2	0.4	3.0	1.0
	GSH/GSSG	16.8	3.4	8.0	3.5

¹SHROB, Spontaneously Hypertensive Obese; WKY, Wistar Kyoto; SOD, superoxide dismutase; CAT, catalase; GR, glutathione reductase; GPx, glutathione peroxidase; GSH, glutathione; GSSG, glutathione disulphide; Hb, haemoglobin.

Statistically significant differences between the samples are indicated by * ($P<0.05$), ** ($P<0.01$) and *** ($P<0.001$).

doi:10.1371/journal.pone.0104637.t002

as increased renal macrophage infiltration [43]. Also, it should be noted that even if total protein carbonylation in SHROB rats is shown to be lower than in WKY rats, we recently reported that key proteins involved in redox homeostasis, such as aldehyde dehydrogenase mitochondrial, protein disulphide-isomerase A3 or protein disulphide-isomerase, suffer higher oxidation in SHROB rats than in WKY rats [44]. Finally, the higher plasma antioxidant

capacity in the SHROB rats, concordant with the lower protein carbonylation found in SHROB plasma may be the result of the activation of defence mechanisms that are not observed to have been overwhelmed in most organs. The observed differences between the different markers of OS, corresponding to different stages and elements of this process, emphasize the need to carry

Table 3. Oxidative stress biomarkers in SHROB and WKY rats (mean value and SEM)¹.

Organ	Parameter	SHROB		WKY	
			SEM		SEM
Plasma	ORAC (μmol Trolox/mL)	44.8*	3.2	30.3	3.6
	LDL-ox (ng/mL)	154.6	21.4	109.0	10.2
	Overall protein oxidation (FTSC intensity)	78.9	12.0	136.0	2.4
Liver	MDA (nmol/mg prot)	9.9	0.8	8.1	1.0
	Overall low ionic strength protein oxidation (FTSC intensity)	51.3*	2.7	74.7	0.7
	Overall high ionic strength protein oxidation (FTSC intensity)	81.4*	6.9	295.7	23.6
Abdominal fat	MDA (nmol/mg prot)	5.6*	1.2	16.0	3.1
Kidney	MDA (nmol/mg prot)	0.7	0.1	0.8	0.1
Heart	MDA (nmol/mg prot)	4.8	0.8	4.3	0.9
Brain	MDA (nmol/mg prot)	28.7	10.0	18.2	1.2
Urine	15-F _{2t} -IsoP (ng/mg creatinine)	2.9	0.2	1.9	0.1

¹SHROB, Spontaneously Hypertensive Obese; WKY, Wistar Kyoto; ORAC, oxygen radical absorbance capacity; MDA, malondialdehyde. Statistically significant differences between the samples are indicated by * ($P < 0.05$), ** ($P < 0.01$) and *** ($P < 0.001$). doi:10.1371/journal.pone.0104637.t003

out this kind of integrated evaluations of OS in *in vivo* studies on metabolic syndrome.

The results presented here provide an updated picture of CVD-related markers in SHROB rats. In blood, the animals show elevated levels of markers related to inflammation, endothelial dysfunction, thrombotic activity, insulin resistance and oxidative stress (C-reactive protein, total cholesterol, LDL-cholesterol, triglycerides, apoA1, apoB100, abdominal fat, blood pressure, ICAM-1 and PAI-1, insulin and oxidized LDL). In other organs (abdominal fat, liver and brain) the glutathione system is activated and oxidative stress remains low, according to the observed concentrations of final lipid and protein oxidation products. All these observations are consistent with a pre-diabetic obese status of SHROB rats with a high risk of developing CVD that may be used to evaluate the effects of nutritional interventions on the metabolic alterations present in MetS.

Supporting Information

Figure S1 Standard curve used to quantify GSH (glutathione).
(DOC)

Figure S2 Standard curve used to quantify GSSG (glutathione disulphide).
(DOC)

References

- Grundy SM (2008) Metabolic syndrome pandemic. *Arterioscler Thromb Vasc Biol* 28: 629–36.
- Eckel RH, Alberti KGMM, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. *The Lancet* 375: 2010, 181–83.
- Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: The insulin resistance atherosclerosis study (IRAS). *Circulation* 102: 42–47.
- Armutcu F, Ataymen M, Atmaca H, Gurel A (2008) Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. *Clin Chem Lab Med* 46: 785–90.
- Güclü F, Özmen B, Hekimsoy Z, Kirmaz C (2004) Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. *Biomed Pharmacother* 58: 614–18.
- Zhang BB, Zhou G, Li C (2009) AMPK: An emerging drug target for diabetes and metabolic syndrome. *Cell Metabolism* 9: 407–16.
- Castell-Auvi A, Cedó L, Pallarés V, Blay MT, Pinent M, et al. (2012) Procyanidins modify insulinemia by affecting insulin production and degradation. *J Nutr Biochem* 23: 1565–72.
- Kimura T, Nakagawa K, Kubota H, Kojima Y, Goto Y, et al. (2007) Food-grade mulberry powder enriched with 1-deoxynojiricin suppresses the elevation of postprandial blood glucose in humans. *J Agric Food Chem* 55: 5869–5874.
- Hariri N, Thibault L (2010) High-fat diet-induced obesity in animal models. *Nutr Res Rev* 23: 270–99.
- Poudyal H, Panchal S, Brown L (2010) Comparison of purple carrot juice and β-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome. *Br J Nutr* 104: 1322–32.
- Chua SC, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, et al. (1996) Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. *Sci* 271: 994–96.
- Koletsky S (1973) Obese spontaneously hypertensive rats: a model for study of atherosclerosis. *Exp Molec Pathol* 19: 53–60.

Figure S3 Representative chromatogram of endogenous 15-F_{2t}-IsoP in rat urine. A) The *m/z* 573 ion current chromatogram represents the [²H₄]-15-F_{2t}-IsoP internal standard; the signal used to quantify 15-F_{2t}-IsoP. B) The *m/z* 569 ion current chromatogram represents endogenous 15-F_{2t}-IsoP. The injection volume was 1 μL.
(DOC)

Figure S4 Evolution of the body weight of SHROB and WKY rats from week 13 to week 27 of life.
(DOC)

Table S1 Fatty acid composition of the soybean oil provided weekly. Values are given as mean ± SD.
(DOC)

Acknowledgments

We thank Lorena Barros and M^a Jesus Gonzalez for technical support, as well as Maria José Bleda Hernández for support with the statistical analysis. Language revision by Christopher Evans is appreciated.

Author Contributions

Conceived and designed the experiments: IM JLT. Performed the experiments: EMT JPJ LL VSM NT MR MP LM AM. Analyzed the data: EMT JPJ SRR MC JLT. Wrote the paper: EMT JPJ SRR.

13. Koletsky S (1975) Animal model of human disease: hypertension, obesity, type 4 hyperlipidemia, vascular disease. *Am J Pathol* 81: 463–66.
14. Takaya K, Ogawa Y, Hiraoka J, Hosoda K, Yamori Y, et al. (1996) Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. *Nature Genetics* 14: 130–31.
15. Ernsberger P, Koletsky RJ, Friedman JE (1999) Molecular pathology in the obese spontaneous hypertensive Koletsky rats: a model of syndrome X. *Annals New York Acad Sci* 892: 315–18.
16. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. *Circul* 120: 1640–45.
17. Ernsberger P, Koletsky RJ (2012) The glucose tolerance test as a laboratory toll with clinical implications. In *Glucose Tolerance* [S Chackrewarthy, editor] InTech 2012.
18. Ishizuka T, Ernsberger P, Liu S (1998) Phenotypic nonsequences of a nonsense mutation in the leptin receptor gene (*fa^b*) in obese spontaneously hypertensive Koletsky rats (SHROB). *J Nutr* 128: 2299–2306.
19. Matthews D, Hosker J, Rudenski A, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28: 412–9.
20. Buñag RD (1973) Validation in awake rats of a tail-cuff method for measuring systolic pressure. *J Appl Physiol* 34: 279–82.
21. Cohen G, Dembic D, Marcus J (1970) Measurement of catalase activity in tissue extracts. *Anal Biochem* 34: 30–38.
22. Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. *J Biol Chem* 247: 3170–3175.
23. Goldberg DM, Spooner RJ (1983) Glutathione reductase. In *Methods of enzymatic analysis*, 3rd ed, pp. 258–265 [HU . Bergmeyer, editor] Weinheim: Verlag Chemie 1983.
24. Wheeler CR, Salzman JA, Elsayed NM, Omaye ST, Korte DW (1990) Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. *Anal Biochem* 184: 193–199.
25. Hissin PJ, Hilf R (1976) A fluorometric method for determination of oxidized and reduced glutathione in tissues. *Anal Biochem* 74: 214–26.
26. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72: 248–254.
27. Drabkin D, Austin J (1935) Spectrophotometric studies. II. Preparations from washed blood cells; nitric oxide hemoglobin and sulfhemoglobin. *J Biol Chem* 112: 51–65.
28. Cao G, Booth SL, Sadowski JA, Prior RL (1998) Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. *Am J Clin Nutr* 68: 1081–1087.
29. Chaudhuri AR, de Waal EM, Pierce A, Van Remmen H, Ward WF, et al. (2006) A detection of protein carbonyls in aging liver tissue: A fluorescence-based proteomic approach. *Mech Ageing Dev* 127: 849–861.
30. Méndez L, Pazos M, Gallardo JM, Torres JL, Pérez-Jiménez J, et al. (2013) Reduced protein oxidation in Wistar rats supplemented with marine omega-3 PUFAs. *Free Radical Biol Med* 55: 8–20.
31. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680–685.
32. Buege JA, Aust SD (1978) Microsomal lipid peroxidation. *Methods Enzymol* 52: 302–10.
33. Milne GL, Sánchez CS, Musiek ES, Morrow DJ (2007) Quantification of F2-isoprostanes as a biomarker of oxidative stress. *Nature Protocols* 2: 221–226.
34. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc C-Appl* 57: 283–90.
35. Simes RJ (1986). An improved bonferroni procedure for multiple tests of significance. *Biometrika* 73: 751–54.
36. Papazzo A, Conlan XA, Lexis L, Lewandowski PA (2011) Differential effects of dietary canola and soybean oil intake on oxidative stress in stroke-prone spontaneously hypertensive rats. *Lipids Health Dis* 10: 98.
37. Mendizábal Y, Llorens S, Nava E (2011) Reactivity of the aortic and mesenteric arteries from the obese spontaneously hypertensive rat: effect of glitazones. *Am J Physiol Heart Circ Physiol* 301:H1319–30.
38. Mendizábal Y, Llorens S, Nava E (2013) Vasoactive effects of prostaglandins from the perivascular fat of mesenteric resistance arteries in WKY and SHROB rats. *Life Sci* 93: 1023–32.
39. Fellman L, Nascimento AR, Tibiriça E, Bousquet P (2012) Murine models for pharmacological studies on the metabolic syndrome. *Pharmacol Therapeut* 137: 331–40.
40. Samuel VT & Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. *Cell* 148: 852–871.
41. Chawla A, Nguyen KD, Goh YPS (2011) Macrophage-mediated inflammation in metabolic disease. *Nat Rev Immunol* 11: 738–49.
42. Maritim AC, Sanders RA, Watkins JB (2003) Diabetes, oxidative stress, and antioxidants: A review. *J Biochem Molec Toxicol* 17: 24–38.
43. Imig JD, Walsh KA, Khan MA, Nagasawa T, Cherian-Shaw M, et al. (2012) Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats. *Exp Biol Med* 237: 1402–12.
44. Méndez L, Pazos M, Giral M, Nogués MR, Pérez-Jiménez J, et al. (2014) Targets of protein carbonylation in Koletsky Spontaneously Hypertensive Obese Rats and healthy Wistar counterparts: a potential role on metabolic disorders. *J Proteom* 106: 246–59.